Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
•This study reports COVID-19 vaccine effectiveness (VE) in real-world settings.•COVID-19 VE for fully and partially vaccinated individuals.•COVID-19 VE for healthcare workers, the elderly, and adults.•The effectiveness of different COVID-19 vaccine brands. To estimate the coronavirus disease 2019 (C...
Saved in:
| Published in | International journal of infectious diseases Vol. 114; pp. 252 - 260 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Canada
Elsevier Ltd
01.01.2022
Zhengzhou University. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | •This study reports COVID-19 vaccine effectiveness (VE) in real-world settings.•COVID-19 VE for fully and partially vaccinated individuals.•COVID-19 VE for healthcare workers, the elderly, and adults.•The effectiveness of different COVID-19 vaccine brands.
To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings.
Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed.
A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6–92.6%), 97.2% (95% CI 96.1–98.3%), 97.4% (95% CI 96.0–98.8%), and 99.0% (95% CI 98.5–99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8–94.4%), 83.8% (95% CI 77.1–90.6%), and 95.3% (95% CI 92.0–98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%.
The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings. |
|---|---|
| AbstractList | •This study reports COVID-19 vaccine effectiveness (VE) in real-world settings.•COVID-19 VE for fully and partially vaccinated individuals.•COVID-19 VE for healthcare workers, the elderly, and adults.•The effectiveness of different COVID-19 vaccine brands.
To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings.
Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed.
A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6–92.6%), 97.2% (95% CI 96.1–98.3%), 97.4% (95% CI 96.0–98.8%), and 99.0% (95% CI 98.5–99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8–94.4%), 83.8% (95% CI 77.1–90.6%), and 95.3% (95% CI 92.0–98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%.
The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings. Objective: To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Methods: Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed. Results: A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6–92.6%), 97.2% (95% CI 96.1–98.3%), 97.4% (95% CI 96.0–98.8%), and 99.0% (95% CI 98.5–99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8–94.4%), 83.8% (95% CI 77.1–90.6%), and 95.3% (95% CI 92.0–98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%. Conclusions: The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings. To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings.OBJECTIVETo estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings.Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed.METHODSStudies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed.A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6-92.6%), 97.2% (95% CI 96.1-98.3%), 97.4% (95% CI 96.0-98.8%), and 99.0% (95% CI 98.5-99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8-94.4%), 83.8% (95% CI 77.1-90.6%), and 95.3% (95% CI 92.0-98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%.RESULTSA total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6-92.6%), 97.2% (95% CI 96.1-98.3%), 97.4% (95% CI 96.0-98.8%), and 99.0% (95% CI 98.5-99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8-94.4%), 83.8% (95% CI 77.1-90.6%), and 95.3% (95% CI 92.0-98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%.The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings.CONCLUSIONSThe COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings. To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed. A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6-92.6%), 97.2% (95% CI 96.1-98.3%), 97.4% (95% CI 96.0-98.8%), and 99.0% (95% CI 98.5-99.6%), respectively. The VE against infection in the general population aged ≥16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8-94.4%), 83.8% (95% CI 77.1-90.6%), and 95.3% (95% CI 92.0-98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%. The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real-world settings. |
| Author | Shao, Weihao Chen, Xiaorui Zheng, Caifang Zhang, Weidong Wang, Gaili Zhang, Bowen |
| Author_xml | – sequence: 1 givenname: Caifang surname: Zheng fullname: Zheng, Caifang – sequence: 2 givenname: Weihao surname: Shao fullname: Shao, Weihao – sequence: 3 givenname: Xiaorui surname: Chen fullname: Chen, Xiaorui – sequence: 4 givenname: Bowen surname: Zhang fullname: Zhang, Bowen – sequence: 5 givenname: Gaili surname: Wang fullname: Wang, Gaili – sequence: 6 givenname: Weidong surname: Zhang fullname: Zhang, Weidong email: imooni@163.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34800687$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk9v1DAQxSNURP_AF-CAcuSSYDux41QICS0UVqpUCRWu1sQeFy_euNjZrfbb43RLRXsoJ4_G7_dm5Ofj4mAMIxbFa0pqSqh4t6rdypmaEUZrSmtC-mfFEZWdrBpO6UGuGaFV31F2WByntCKEtELIF8Vh00pChOyOistvCL66CdGbEq1FPbktjphSGWy5uPix_FTRvtyC1i53T0sovZswwrSJWEbcOrwpYTTlGieoYAS_Sy69LJ5b8Alf3Z0nxfezz5eLr9X5xZfl4uN5pUUjp6rVBjga7JnRw2DEYIbBUmIbDkQ20HQcgWrIxcBaw4aBt8JqbnkDXEsjm5Niufc1AVbqOro1xJ0K4NRtI8QrBXFy2qMSbcepsGikyV6C9RaZsUAGJiUyYbPXh73X9WZYo9E4ThH8A9OHN6P7qa7CVkne877j2eDtnUEMvzeYJrV2SaP3MGLYJMUEIUy2TTfv_ebfWfdD_saSBWwv0DGkFNHeSyhRc_Zqpebs1Zy9olTl7DMkH0HaTTC5MO_r_NPo-z2KOa2caVRJOxw1Ghfzl8jP6Z7GTx_h2rvRafC_cPc_-A-Cxd8z |
| CitedBy_id | crossref_primary_10_1016_j_jcms_2024_06_008 crossref_primary_10_1111_bcp_15552 crossref_primary_10_1007_s00894_022_05286_6 crossref_primary_10_1016_j_ajic_2022_05_028 crossref_primary_10_3389_fpsyg_2022_985728 crossref_primary_10_1038_s41390_022_02374_4 crossref_primary_10_1080_07391102_2021_2024260 crossref_primary_10_1017_S095026882300153X crossref_primary_10_1016_j_health_2023_100241 crossref_primary_10_1080_13697137_2024_2385360 crossref_primary_10_58931_cht_2023_2231 crossref_primary_10_3389_fimmu_2023_1220600 crossref_primary_10_1183_23120541_00096_2024 crossref_primary_10_5144_0256_4947_2024_306 crossref_primary_10_1027_2698_1866_a000064 crossref_primary_10_1080_17441692_2023_2172199 crossref_primary_10_3390_su15107740 crossref_primary_10_1016_j_semerg_2024_102343 crossref_primary_10_3390_healthcare11101467 crossref_primary_10_3390_vaccines13030220 crossref_primary_10_1057_s41271_022_00357_7 crossref_primary_10_3390_biomedicines12061248 crossref_primary_10_3389_fpubh_2024_1348170 crossref_primary_10_1016_j_puhe_2023_08_004 crossref_primary_10_1080_21645515_2022_2157622 crossref_primary_10_2174_1381612828666220701160116 crossref_primary_10_1039_D1CS01170G crossref_primary_10_1186_s12941_023_00594_y crossref_primary_10_3389_fpubh_2024_1343950 crossref_primary_10_3389_fimmu_2024_1328905 crossref_primary_10_3389_fpsyt_2022_832352 crossref_primary_10_1371_journal_pone_0291131 crossref_primary_10_1016_j_medcle_2023_11_030 crossref_primary_10_1097_MD_0000000000035987 crossref_primary_10_1302_0301_620X_104B12_BJJ_2022_0843_R1 crossref_primary_10_1371_journal_pgph_0001845 crossref_primary_10_3390_vaccines10071142 crossref_primary_10_3389_fncel_2024_1481963 crossref_primary_10_3346_jkms_2022_37_e175 crossref_primary_10_3390_ijms24108746 crossref_primary_10_3389_fpubh_2024_1348015 crossref_primary_10_3390_vaccines12050553 crossref_primary_10_1016_j_ensci_2024_100511 crossref_primary_10_1016_j_lana_2024_100774 crossref_primary_10_1016_j_jiph_2025_102688 crossref_primary_10_3390_healthcare11030288 crossref_primary_10_1136_bmjopen_2023_073555 crossref_primary_10_3389_fimmu_2024_1450114 crossref_primary_10_3389_fpubh_2022_959073 crossref_primary_10_3389_fpubh_2024_1415178 crossref_primary_10_1007_s10875_022_01325_2 crossref_primary_10_2478_ejis_2023_0007 crossref_primary_10_3390_cancers14174334 crossref_primary_10_1111_spc3_12809 crossref_primary_10_1016_j_vaccine_2022_10_043 crossref_primary_10_1016_j_jinf_2023_01_016 crossref_primary_10_1021_acs_jpcb_3c06714 crossref_primary_10_56936_18290825_2022_16_2_14 crossref_primary_10_3390_healthcare11091235 crossref_primary_10_4103_jehp_jehp_440_23 crossref_primary_10_1080_07853890_2023_2241351 crossref_primary_10_1016_j_diabres_2023_110694 crossref_primary_10_3390_microorganisms11122959 crossref_primary_10_1007_s11673_022_10223_6 crossref_primary_10_20473_ijtid_v12i2_45606 crossref_primary_10_3390_vaccines10071155 crossref_primary_10_1007_s10067_022_06149_4 crossref_primary_10_1016_j_athoracsur_2023_05_048 crossref_primary_10_3390_vaccines10071035 crossref_primary_10_1186_s12916_023_02861_3 crossref_primary_10_24193_subbbiol_2024_1_01 crossref_primary_10_1016_j_vacune_2024_02_010 crossref_primary_10_1371_journal_pone_0267001 crossref_primary_10_3390_vaccines11101512 crossref_primary_10_1051_bioconf_20237505022 crossref_primary_10_25005_2074_0581_2022_24_1_113_122 crossref_primary_10_1111_eci_14286 crossref_primary_10_3390_ijerph191912422 crossref_primary_10_1007_s40259_023_00611_8 crossref_primary_10_12688_f1000research_110281_1 crossref_primary_10_3390_jcm12020628 crossref_primary_10_1159_000542281 crossref_primary_10_1016_j_jse_2023_07_040 crossref_primary_10_3390_ijerph19074056 crossref_primary_10_3390_vaccines10071080 crossref_primary_10_1111_spc3_12878 crossref_primary_10_1016_j_jddst_2023_105049 crossref_primary_10_1007_s40819_022_01316_2 crossref_primary_10_1007_s40496_024_00369_0 crossref_primary_10_1016_j_clim_2023_109882 crossref_primary_10_1111_twec_13619 crossref_primary_10_1016_j_ccc_2024_05_010 crossref_primary_10_3389_fimmu_2025_1501609 crossref_primary_10_1016_j_hrtlng_2024_06_002 crossref_primary_10_1371_journal_pgph_0003820 crossref_primary_10_1136_bmj_2023_076990 crossref_primary_10_1007_s40121_024_01082_2 crossref_primary_10_1016_j_medcli_2023_11_035 crossref_primary_10_1007_s40265_024_02013_8 crossref_primary_10_1007_s43440_022_00429_1 crossref_primary_10_1017_S0033291724001983 crossref_primary_10_1017_ash_2023_447 crossref_primary_10_61873_SVRL5228 crossref_primary_10_1016_j_cell_2023_04_024 crossref_primary_10_1016_j_ajcnut_2022_11_011 crossref_primary_10_3389_fpubh_2023_1192709 crossref_primary_10_3390_jcm12165279 crossref_primary_10_3390_pharmaceutics15020667 crossref_primary_10_3389_fbrio_2023_1258159 crossref_primary_10_1136_bmjopen_2022_065687 crossref_primary_10_12688_f1000research_145862_1 crossref_primary_10_30629_0023_2149_2022_100_9_10_474_478 crossref_primary_10_1098_rsta_2022_0156 crossref_primary_10_1016_j_ssmph_2023_101574 crossref_primary_10_1016_j_vaccine_2022_10_080 crossref_primary_10_3390_vaccines12020189 crossref_primary_10_3390_ijtm4010004 crossref_primary_10_1016_j_idm_2024_02_010 crossref_primary_10_3389_fpubh_2024_1429265 crossref_primary_10_1016_j_paid_2022_111524 crossref_primary_10_3390_ijms24010250 crossref_primary_10_1016_j_medine_2025_502167 crossref_primary_10_3390_v14051049 crossref_primary_10_1038_s41467_023_37795_0 crossref_primary_10_1016_j_vaccine_2024_04_049 crossref_primary_10_1097_CM9_0000000000002767 crossref_primary_10_3389_fimmu_2023_1255676 crossref_primary_10_1002_jmv_29676 crossref_primary_10_1016_j_arr_2023_102138 crossref_primary_10_1111_hex_70025 crossref_primary_10_3390_vaccines11081342 crossref_primary_10_1016_j_ijid_2024_107012 crossref_primary_10_1016_j_artmed_2024_102980 crossref_primary_10_2147_JMDH_S455396 crossref_primary_10_1155_2022_6505990 crossref_primary_10_1093_aje_kwad199 crossref_primary_10_3389_ijph_2023_1605526 crossref_primary_10_1177_08850666241281281 crossref_primary_10_1590_1413_812320232810_09652023 crossref_primary_10_4103_ijo_IJO_946_22 crossref_primary_10_1007_s00894_024_06006_y crossref_primary_10_1080_10410236_2023_2165257 crossref_primary_10_3988_jcn_2022_0348 crossref_primary_10_16899_jcm_1220724 crossref_primary_10_46234_ccdcw2022_048 crossref_primary_10_3934_mbe_2022307 crossref_primary_10_7774_cevr_2024_13_3_225 crossref_primary_10_1016_j_jvacx_2024_100458 crossref_primary_10_2139_ssrn_4151508 crossref_primary_10_1016_j_vaccine_2025_127003 crossref_primary_10_3389_fimmu_2022_947602 crossref_primary_10_1152_ajpendo_00064_2022 crossref_primary_10_3389_fmicb_2024_1334152 crossref_primary_10_1016_j_vaccine_2024_04_029 crossref_primary_10_1016_j_vaccine_2025_127002 crossref_primary_10_1136_bmjresp_2023_002234 crossref_primary_10_54005_geneltip_1346388 crossref_primary_10_3390_vaccines11081325 crossref_primary_10_1016_j_socscimed_2023_115695 crossref_primary_10_1177_17456916231178720 crossref_primary_10_1186_s12889_024_17957_5 crossref_primary_10_3390_vaccines11050985 crossref_primary_10_1016_j_epidem_2024_100744 crossref_primary_10_1016_j_jvacx_2024_100488 crossref_primary_10_3390_vaccines10050753 crossref_primary_10_3390_ijerph20031912 crossref_primary_10_1016_j_jogc_2023_102239 crossref_primary_10_2807_1560_7917_ES_2024_29_34_2300503 crossref_primary_10_1016_j_vaccine_2023_09_018 crossref_primary_10_3389_fpsyt_2024_1402194 crossref_primary_10_1080_21645515_2023_2275962 crossref_primary_10_1146_annurev_immunol_101721_061120 crossref_primary_10_1016_j_cmi_2022_06_026 crossref_primary_10_3389_fmed_2023_1155727 crossref_primary_10_1001_jamanetworkopen_2024_37388 crossref_primary_10_1177_21582440241251471 crossref_primary_10_1186_s12941_023_00569_z crossref_primary_10_3390_vaccines10071009 crossref_primary_10_1093_ndt_gfad127 crossref_primary_10_3390_vaccines12060657 crossref_primary_10_1039_D2NJ02744E crossref_primary_10_1371_journal_pone_0304110 crossref_primary_10_3346_jkms_2023_38_e106 crossref_primary_10_2196_44465 crossref_primary_10_55517_mrr_1220166 crossref_primary_10_1016_S2665_9913_22_00096_0 crossref_primary_10_1080_21645515_2023_2220630 crossref_primary_10_3390_vaccines10050779 crossref_primary_10_1021_acs_jmedchem_2c01998 crossref_primary_10_1097_MD_0000000000032068 crossref_primary_10_1016_j_jpsychires_2022_04_042 crossref_primary_10_33590_emj_22F0322 crossref_primary_10_1038_s41598_024_84100_0 crossref_primary_10_7326_M23_1894 crossref_primary_10_1111_cbdd_14179 crossref_primary_10_3346_jkms_2023_38_e214 crossref_primary_10_3389_fchem_2023_1252996 crossref_primary_10_3390_vaccines10040608 crossref_primary_10_1016_j_isci_2025_112091 crossref_primary_10_1097_PPO_0000000000000661 crossref_primary_10_5993_AJHB_46_4_4 crossref_primary_10_1007_s11357_023_00931_1 crossref_primary_10_1016_j_jvacx_2024_100496 crossref_primary_10_1016_j_worlddev_2024_106762 crossref_primary_10_3390_covid3020017 crossref_primary_10_1093_aje_kwac157 crossref_primary_10_1186_s13584_022_00548_3 crossref_primary_10_1016_j_clinsp_2022_100109 crossref_primary_10_1186_s12651_024_00376_9 crossref_primary_10_3389_fpsyg_2024_1437942 crossref_primary_10_1001_jamanetworkopen_2022_54777 crossref_primary_10_1007_s40267_024_01124_2 crossref_primary_10_3390_vaccines11040849 crossref_primary_10_3390_vaccines12050514 crossref_primary_10_1590_s2237_96222024v33e2023214_pt crossref_primary_10_17816_EID624001 crossref_primary_10_1186_s12929_023_00977_5 crossref_primary_10_1038_s41598_022_22014_5 crossref_primary_10_1007_s00431_023_04982_6 crossref_primary_10_1186_s12954_023_00826_6 crossref_primary_10_1002_cti2_1434 crossref_primary_10_3390_v15020272 crossref_primary_10_3390_v16010114 crossref_primary_10_1016_j_vaccine_2024_03_018 crossref_primary_10_1038_s41598_024_84379_z crossref_primary_10_3390_jcm13154308 crossref_primary_10_3390_biomedicines10123069 crossref_primary_10_1016_j_vaccine_2024_04_050 crossref_primary_10_1128_jvi_01912_23 crossref_primary_10_3390_vaccines10101712 crossref_primary_10_57187_s_3708 crossref_primary_10_3390_v14040759 crossref_primary_10_3389_fpubh_2024_1367480 crossref_primary_10_3748_wjg_v29_i5_800 crossref_primary_10_1016_j_jvacx_2024_100508 crossref_primary_10_1007_s13555_022_00803_0 crossref_primary_10_1016_j_heliyon_2024_e30760 crossref_primary_10_3390_jcm11247275 crossref_primary_10_1038_s41562_023_01733_3 crossref_primary_10_1093_aje_kwae209 crossref_primary_10_3390_jpm13020259 crossref_primary_10_3390_vaccines10020146 crossref_primary_10_3390_covid4060050 crossref_primary_10_1177_00469580221143630 crossref_primary_10_1186_s12916_023_02847_1 crossref_primary_10_2147_IJN_S423251 crossref_primary_10_1016_j_medj_2024_02_008 crossref_primary_10_3390_life12071066 crossref_primary_10_3390_v15051171 crossref_primary_10_1038_s41562_023_01591_z crossref_primary_10_1007_s11684_023_0991_0 crossref_primary_10_1186_s12879_023_08748_1 crossref_primary_10_1111_cts_70137 crossref_primary_10_3389_fchem_2024_1379192 crossref_primary_10_1371_journal_pgph_0002493 crossref_primary_10_1007_s40258_023_00796_7 crossref_primary_10_3390_ijms231911851 crossref_primary_10_1177_10105395241240952 crossref_primary_10_1007_s40121_024_00936_z crossref_primary_10_1016_j_vaccine_2023_07_035 crossref_primary_10_7454_msk_v27i1_1404 crossref_primary_10_1038_s41467_024_52342_1 crossref_primary_10_2147_IJGM_S431179 crossref_primary_10_3390_vaccines10122029 crossref_primary_10_1016_j_ajic_2023_02_005 crossref_primary_10_13181_mji_bc_226066 crossref_primary_10_1371_journal_pgph_0003474 crossref_primary_10_3390_vaccines11071260 crossref_primary_10_3389_fcimb_2024_1347710 crossref_primary_10_2147_IDR_S390947 crossref_primary_10_3390_jcm12206458 crossref_primary_10_3390_vaccines11030507 crossref_primary_10_1002_dmrr_3666 crossref_primary_10_1265_ehpm_24_00191 crossref_primary_10_1371_journal_pone_0275425 crossref_primary_10_1093_ofid_ofad355 crossref_primary_10_3389_ijph_2023_1605736 crossref_primary_10_1007_s40121_024_01020_2 crossref_primary_10_1016_j_envres_2025_121047 crossref_primary_10_1016_j_jtha_2024_12_021 crossref_primary_10_1007_s40121_024_01079_x crossref_primary_10_3390_vaccines11030638 crossref_primary_10_1016_j_puhe_2022_10_005 crossref_primary_10_3390_vaccines10081215 crossref_primary_10_1038_s41541_024_00830_2 crossref_primary_10_3390_vaccines11010171 crossref_primary_10_1002_cpt_2603 crossref_primary_10_1590_s2237_96222024v33e2023214_en crossref_primary_10_1016_j_jiph_2023_11_005 crossref_primary_10_1016_j_jvacx_2023_100393 crossref_primary_10_1186_s12879_024_09139_w crossref_primary_10_3389_fonc_2024_1380492 crossref_primary_10_3390_vaccines10091481 crossref_primary_10_54393_fbt_v3i02_47 crossref_primary_10_5937_medi56_45203 crossref_primary_10_1016_j_cytogfr_2022_10_003 crossref_primary_10_1016_j_jiph_2023_05_018 crossref_primary_10_1016_j_jiph_2022_03_006 crossref_primary_10_1007_s41471_022_00132_0 crossref_primary_10_1080_21645515_2024_2316417 crossref_primary_10_1016_j_jfma_2024_06_027 crossref_primary_10_3390_vaccines12030315 crossref_primary_10_3390_v14122620 crossref_primary_10_3961_jpmph_23_162 crossref_primary_10_1016_j_amc_2024_129214 crossref_primary_10_3389_fpubh_2022_983571 crossref_primary_10_3390_vaccines12121359 crossref_primary_10_4025_ciencuidsaude_v22i0_66049 crossref_primary_10_1039_D3OB00381G crossref_primary_10_1111_resp_14236 crossref_primary_10_3390_cancers14225537 crossref_primary_10_1186_s12916_022_02663_z crossref_primary_10_7759_cureus_57320 crossref_primary_10_1186_s12916_023_03025_z crossref_primary_10_3389_fmedt_2022_867982 crossref_primary_10_1016_j_ajmo_2024_100068 crossref_primary_10_1136_bmjgh_2023_014247 crossref_primary_10_1016_j_mbs_2024_109337 crossref_primary_10_1093_infdis_jiaf001 crossref_primary_10_1038_s41598_022_21369_z crossref_primary_10_3389_fpsyg_2022_1035458 crossref_primary_10_1038_s41467_024_48207_2 crossref_primary_10_1016_j_vaccine_2024_126582 crossref_primary_10_3390_vaccines12121365 crossref_primary_10_1016_j_jvacx_2023_100371 crossref_primary_10_1016_j_vacun_2023_10_002 crossref_primary_10_1038_s41467_025_56994_5 crossref_primary_10_1021_acs_jmedchem_2c01131 crossref_primary_10_1590_1413_812320232810_09652023en crossref_primary_10_1016_j_molimm_2023_09_001 crossref_primary_10_1080_19317611_2022_2163446 crossref_primary_10_1093_ofid_ofac469 crossref_primary_10_1016_j_carres_2024_109205 crossref_primary_10_3390_vaccines10101676 crossref_primary_10_3390_v15122395 crossref_primary_10_1093_ejcts_ezae120 crossref_primary_10_1186_s12879_024_09654_w crossref_primary_10_3390_antib11040070 crossref_primary_10_2139_ssrn_4181714 crossref_primary_10_1186_s40001_023_01210_7 crossref_primary_10_1093_ije_dyac199 crossref_primary_10_1186_s40164_023_00426_x crossref_primary_10_3390_idr15010004 crossref_primary_10_3390_vaccines11051011 crossref_primary_10_3390_su151511572 crossref_primary_10_1016_j_ssmph_2023_101568 crossref_primary_10_3389_fpubh_2024_1437388 crossref_primary_10_3390_pharmacy10050137 crossref_primary_10_3390_tropicalmed8040227 crossref_primary_10_1016_j_ijbiomac_2023_127344 crossref_primary_10_1016_j_vhri_2023_03_005 crossref_primary_10_3390_ijerph20043481 crossref_primary_10_3389_fimmu_2023_1172851 crossref_primary_10_1016_j_gastre_2024_502202 crossref_primary_10_1016_j_vaccine_2024_126565 crossref_primary_10_2174_1570162X20666220823110435 crossref_primary_10_1016_j_yebeh_2023_109387 crossref_primary_10_1371_journal_pone_0282271 crossref_primary_10_3390_vaccines11030564 crossref_primary_10_1080_21645515_2024_2353491 crossref_primary_10_1016_j_jmii_2023_12_002 crossref_primary_10_3390_ani13040550 crossref_primary_10_3390_healthcare12100979 crossref_primary_10_3390_systems11050220 crossref_primary_10_1186_s12889_023_15171_3 crossref_primary_10_1016_j_neuro_2022_03_012 crossref_primary_10_37989_gumussagbil_1271608 crossref_primary_10_1007_s11739_022_03028_3 crossref_primary_10_1038_s44321_024_00065_7 crossref_primary_10_1038_s41598_022_10097_z crossref_primary_10_3390_diseases12090199 crossref_primary_10_3390_vaccines11020281 crossref_primary_10_3389_fimmu_2022_894543 crossref_primary_10_1186_s11658_022_00352_6 crossref_primary_10_3390_ijms25021330 crossref_primary_10_1093_oodh_oqae005 crossref_primary_10_1017_ice_2023_95 crossref_primary_10_1126_science_abq0839 crossref_primary_10_3389_fpubh_2022_917732 crossref_primary_10_3390_v15030675 crossref_primary_10_3390_jcm11164723 crossref_primary_10_3390_vaccines12010103 crossref_primary_10_3390_v15030678 crossref_primary_10_1016_j_jinf_2024_106358 crossref_primary_10_1002_eji_202451236 crossref_primary_10_1093_inthealth_ihae019 crossref_primary_10_1016_j_ejca_2022_05_029 crossref_primary_10_3390_vaccines11020273 crossref_primary_10_1016_j_vaccine_2023_06_066 crossref_primary_10_1186_s12889_022_14025_8 crossref_primary_10_1371_journal_pgph_0003071 crossref_primary_10_1055_s_0042_1757634 crossref_primary_10_1002_smi_3423 crossref_primary_10_3390_vaccines11091502 crossref_primary_10_1038_s41586_022_05398_2 crossref_primary_10_3389_fimmu_2022_965971 crossref_primary_10_4236_aid_2024_141008 crossref_primary_10_1002_pds_5724 crossref_primary_10_3390_jcm12185812 crossref_primary_10_1371_journal_pone_0270485 crossref_primary_10_1016_j_isci_2023_107612 crossref_primary_10_1080_22221751_2022_2122582 crossref_primary_10_1515_cclm_2024_0036 crossref_primary_10_1016_j_rcsop_2024_100520 crossref_primary_10_1039_D3TB02895J crossref_primary_10_1038_s41598_022_16759_2 crossref_primary_10_3390_jcm11195787 crossref_primary_10_1080_17441692_2023_2264968 crossref_primary_10_3390_biom12091302 crossref_primary_10_3390_vaccines12020211 crossref_primary_10_1093_ofid_ofae388 crossref_primary_10_1371_journal_pone_0308139 crossref_primary_10_3390_microorganisms13010135 crossref_primary_10_1007_s11739_023_03231_w crossref_primary_10_3390_vaccines11020369 crossref_primary_10_3390_ijms24043537 crossref_primary_10_3390_microorganisms10081666 crossref_primary_10_3389_fendo_2022_1027047 crossref_primary_10_3390_covid2120128 crossref_primary_10_1016_j_lana_2022_100418 crossref_primary_10_15406_ijvv_2022_07_00112 crossref_primary_10_1093_rpsppr_rqad020 crossref_primary_10_3390_ijerph192114591 crossref_primary_10_1016_j_gastrohep_2024_502202 crossref_primary_10_1016_j_pmedr_2024_102632 crossref_primary_10_1080_13696998_2022_2071427 crossref_primary_10_1001_jamahealthforum_2024_2006 crossref_primary_10_1016_j_eclinm_2022_101624 crossref_primary_10_1016_S1473_3099_22_00140_2 crossref_primary_10_3389_fdsfr_2023_1235051 crossref_primary_10_1093_rheumatology_keac604 crossref_primary_10_1109_TCSS_2024_3404236 crossref_primary_10_3390_vaccines12111284 crossref_primary_10_1098_rsos_230377 crossref_primary_10_1186_s12879_024_09865_1 crossref_primary_10_3389_fmed_2023_1176168 crossref_primary_10_3390_vaccines12030254 crossref_primary_10_1016_j_vaccine_2022_10_007 crossref_primary_10_3389_fimmu_2022_974433 |
| Cites_doi | 10.15585/mmwr.mm6912e2 10.1016/S0140-6736(21)00947-8 10.1016/S1473-3099(21)00289-9 10.1056/NEJMoa2102214 10.1001/jama.2020.2648 10.1136/bmj.n1088 10.1016/S1473-3099(13)70046-X 10.1056/NEJMc2104974 10.1056/NEJMc2035906 10.1056/NEJMoa2101544 10.1016/j.vaccine.2021.06.011 10.1056/NEJMoa2107715 10.1136/bmj.n71 10.1016/S0140-6736(20)30566-3 10.1016/j.vaccine.2010.10.023 10.1186/s12877-020-01954-5 10.1056/NEJMc2036242 10.1016/j.ijid.2021.05.021 10.1016/j.smim.2018.10.010 10.1001/jamanetworkopen.2021.15985 10.1056/NEJMoa2101765 10.1016/S0140-6736(20)32661-1 10.1056/NEJMoa2035389 10.1016/j.therap.2021.05.004 10.1093/ofid/ofab262 10.1186/s13063-020-04775-4 10.1111/jgs.17180 10.15585/mmwr.mm7011e3 10.1136/bmj.n2015 10.1016/j.cmi.2021.06.036 10.1016/j.vaccine.2021.05.099 |
| ContentType | Journal Article |
| Copyright | 2021 Zhengzhou University Copyright © 2021 Zhengzhou University. Published by Elsevier Ltd.. All rights reserved. 2021 Zhengzhou University 2021 |
| Copyright_xml | – notice: 2021 Zhengzhou University – notice: Copyright © 2021 Zhengzhou University. Published by Elsevier Ltd.. All rights reserved. – notice: 2021 Zhengzhou University 2021 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ijid.2021.11.009 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals (ODIN) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1878-3511 |
| EndPage | 260 |
| ExternalDocumentID | oai_doaj_org_article_647516fed8d24d629fe2dfa0b288e26f PMC8595975 34800687 10_1016_j_ijid_2021_11_009 S1201971221008572 |
| Genre | Meta-Analysis Journal Article Review |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-4cda5ede92dcbbd6bdbbf10f35a083a375ea1caa37b24d2bb546fc5f53a5c8d83 |
| IEDL.DBID | .~1 |
| ISSN | 1201-9712 1878-3511 |
| IngestDate | Wed Aug 27 01:08:09 EDT 2025 Thu Aug 21 13:54:32 EDT 2025 Fri Jul 11 14:36:45 EDT 2025 Thu Apr 03 06:57:22 EDT 2025 Tue Jul 01 04:30:09 EDT 2025 Thu Apr 24 22:50:26 EDT 2025 Fri Feb 23 02:40:48 EST 2024 Tue Aug 26 16:32:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 SARS-CoV-2 Vaccine Effectiveness Real-world |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2021 Zhengzhou University. Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-4cda5ede92dcbbd6bdbbf10f35a083a375ea1caa37b24d2bb546fc5f53a5c8d83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Caifang Zheng and Weihao Shao contributed equally to this manuscript. |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1201971221008572 |
| PMID | 34800687 |
| PQID | 2600284378 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_647516fed8d24d629fe2dfa0b288e26f pubmedcentral_primary_oai_pubmedcentral_nih_gov_8595975 proquest_miscellaneous_2600284378 pubmed_primary_34800687 crossref_primary_10_1016_j_ijid_2021_11_009 crossref_citationtrail_10_1016_j_ijid_2021_11_009 elsevier_sciencedirect_doi_10_1016_j_ijid_2021_11_009 elsevier_clinicalkey_doi_10_1016_j_ijid_2021_11_009 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-01 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | International journal of infectious diseases |
| PublicationTitleAlternate | Int J Infect Dis |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Zhengzhou University. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Zhengzhou University. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases – name: Elsevier |
| References | Prendki, Tau, Avni, Falcone, Huttner, Kaiser (bib0026) 2020; 20 Brosh-Nissimov, Orenbuch-Harroch, Chowers, Elbaz, Nesher, Stein (bib0005) 2021 Jones, Rivett, Seaman, Samworth, Warne, Workman (bib0015) 2021 Dagan, Barda, Kepten, Miron, Perchik, Katz (bib0008) 2021; 384 2021. Ministerio de Salud. "Efectividad de la vacuna CoronaVac con virus inactivo contra SARS-CoV-2 en Chile" Retrieved June 18, 2021, from Madhi, Baillie, Cutland, Voysey, Koen, Fairlie (bib0020) 2021; 384 ‘metafor’ P. Package ‘metafor’."Meta-Analysis Package for R." Retrieved June 9, 2021, from CDC COVID-19 Response Team (bib0034) 2020; 69 Frasca, Diaz, Romero, Landin, Phillips, Lechner (bib0010) 2010; 28 Lipsitch, Kahn (bib0018) 2021; 39 Wu, McGoogan (bib0039) 2020; 323 Rudolph, Hartronft, McConeghy, Kennedy, Intrator, Minor (bib0028) 2021 Gomez, Perdiguero, Esteban (bib0011) 2021; 9 Skowronski, De Serres (bib0032) 2021; 384 Wells. G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2011. Retrieved July 07, 2021, from Baden, El Sahly, Essink, Kotloff, Frey, Novak (bib0003) 2021; 384 Tande, Pollock, Shah, Farrugia, Virk, Swift (bib0033) 2021 Ciabattini, Nardini, Santoro, Garagnani, Franceschi, Medaglini (bib0007) 2018; 40 Pawlowski, Lenehan, Puranik, Agarwal, Venkatakrishnan, Niesen (bib0025) 2021 Abu-Raddad, Chemaitelly, Butt (bib0002) 2021; 385 Lopez Bernal, Andrews, Gower, Robertson, Stowe, Tessier (bib0019) 2021; 373 McElhaney, Beran, Devaster, Esen, Launay, Leroux-Roels (bib0021) 2013; 13 WHO. World Health Organization. "Tracking SARS-CoV-2 variants." Retrieved July 07, 2021, from https://www.who.int/activities/tracking-SARS-CoV-2-variants/tracking-SARS-CoV-2-variants. 2021a. Chodick, Tene, Patalon, Gazit, Ben Tov, Cohen (bib0006) 2021; 4 Ranzani, Hitchings, Dorion, D'Agostini, de Paula, de Paula (bib0027) 2021; 374 Zhou, Yu, Du, Fan, Liu, Liu (bib0042) 2020; 395 Jara, Undurraga, Gonzalez, Paredes, Fontecilla, Jara (bib0014) 2021 WHO. World Health Organization. ‘‘WHO Coronavirus Disease (COVID-19) Dashboard.” Retrieved October 15, 2021, from https://covid19.who.int/. 2021b. Deplanque, Launay (bib0009) 2021 . Zacay, Shasha, Bareket, Kadim, Hershkowitz Sikron, Tsamir (bib0040) 2021; 8 Patel, Bergeri, Bresee, Cowling, Crowcroft, Fahmy (bib0024) 2021 Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (bib0035) 2021; 397 Sadoff, Gray, Vandebosch, Cardenas, Shukarev, Grinsztejn (bib0029) 2021; 384 Haas, Angulo, McLaughlin, Anis, Singer, Khan (bib0012) 2021; 397 Li, Huang, Wang, Jing, Zhang, Qin (bib0017) 2021 Zaqout, Daghfal, Alaqad, Hussein, Aldushain, Almaslamani (bib0041) 2021; 108 Britton, Jacobs Slifka, Edens, Nanduri, Bart, Shang (bib0004) 2021; 70 Palacios, Patino, de Oliveira Piorelli, Conde, Batista, Zeng (bib0023) 2020; 21 Hitchings, Ranzani, Torres, de Oliveira, Almiron, Said (bib0013) 2021 Krutikov, Hayward, Shallcross (bib0016) 2021; 384 Shrotri, Krutikov, Palmer, Giddings, Azmi, Subbarao (bib0031) 2021 Page, McKenzie, Bossuyt, Boutron, Hoffmann, Mulrow (bib0022) 2021; 372 Jara (10.1016/j.ijid.2021.11.009_bib0014) 2021 Prendki (10.1016/j.ijid.2021.11.009_bib0026) 2020; 20 Abu-Raddad (10.1016/j.ijid.2021.11.009_bib0002) 2021; 385 10.1016/j.ijid.2021.11.009_bib0030 Lipsitch (10.1016/j.ijid.2021.11.009_bib0018) 2021; 39 Pawlowski (10.1016/j.ijid.2021.11.009_bib0025) 2021 Deplanque (10.1016/j.ijid.2021.11.009_bib0009) 2021 Sadoff (10.1016/j.ijid.2021.11.009_bib0029) 2021; 384 10.1016/j.ijid.2021.11.009_bib0036 10.1016/j.ijid.2021.11.009_bib0037 10.1016/j.ijid.2021.11.009_bib0038 Jones (10.1016/j.ijid.2021.11.009_bib0015) 2021 Palacios (10.1016/j.ijid.2021.11.009_bib0023) 2020; 21 Zhou (10.1016/j.ijid.2021.11.009_bib0042) 2020; 395 Rudolph (10.1016/j.ijid.2021.11.009_bib0028) 2021 Gomez (10.1016/j.ijid.2021.11.009_bib0011) 2021; 9 Haas (10.1016/j.ijid.2021.11.009_bib0012) 2021; 397 Shrotri (10.1016/j.ijid.2021.11.009_bib0031) 2021 Zacay (10.1016/j.ijid.2021.11.009_bib0040) 2021; 8 Skowronski (10.1016/j.ijid.2021.11.009_bib0032) 2021; 384 Voysey (10.1016/j.ijid.2021.11.009_bib0035) 2021; 397 Li (10.1016/j.ijid.2021.11.009_bib0017) 2021 Patel (10.1016/j.ijid.2021.11.009_bib0024) 2021 Madhi (10.1016/j.ijid.2021.11.009_bib0020) 2021; 384 Lopez Bernal (10.1016/j.ijid.2021.11.009_bib0019) 2021; 373 10.1016/j.ijid.2021.11.009_bib0001 Krutikov (10.1016/j.ijid.2021.11.009_bib0016) 2021; 384 Baden (10.1016/j.ijid.2021.11.009_bib0003) 2021; 384 Hitchings (10.1016/j.ijid.2021.11.009_bib0013) 2021 Britton (10.1016/j.ijid.2021.11.009_bib0004) 2021; 70 Wu (10.1016/j.ijid.2021.11.009_bib0039) 2020; 323 Frasca (10.1016/j.ijid.2021.11.009_bib0010) 2010; 28 McElhaney (10.1016/j.ijid.2021.11.009_bib0021) 2013; 13 Page (10.1016/j.ijid.2021.11.009_bib0022) 2021; 372 CDC COVID-19 Response Team (10.1016/j.ijid.2021.11.009_bib0034) 2020; 69 Chodick (10.1016/j.ijid.2021.11.009_bib0006) 2021; 4 Brosh-Nissimov (10.1016/j.ijid.2021.11.009_bib0005) 2021 Dagan (10.1016/j.ijid.2021.11.009_bib0008) 2021; 384 Ranzani (10.1016/j.ijid.2021.11.009_bib0027) 2021; 374 Zaqout (10.1016/j.ijid.2021.11.009_bib0041) 2021; 108 Ciabattini (10.1016/j.ijid.2021.11.009_bib0007) 2018; 40 Tande (10.1016/j.ijid.2021.11.009_bib0033) 2021 |
| References_xml | – volume: 384 start-page: 2187 year: 2021 end-page: 2201 ident: bib0029 article-title: Safety and Effectiveness of Single-Dose Ad26.COV2.S Vaccine against Covid-19 publication-title: N Engl J Med – start-page: 10 year: 2021 ident: bib0015 article-title: Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection publication-title: Elife – volume: 385 start-page: 187 year: 2021 end-page: 189 ident: bib0002 article-title: National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants publication-title: N Engl J Med – volume: 40 start-page: 83 year: 2018 end-page: 94 ident: bib0007 article-title: Vaccination in the elderly: The challenge of immune changes with aging publication-title: Semin Immunol – volume: 13 start-page: 485 year: 2013 end-page: 496 ident: bib0021 article-title: AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial publication-title: Lancet Infect Dis – reference: ‘metafor’ P. Package ‘metafor’."Meta-Analysis Package for R." Retrieved June 9, 2021, from – year: 2021 ident: bib0005 article-title: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel publication-title: Clin Microbiol Infect – volume: 4 year: 2021 ident: bib0006 article-title: Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization publication-title: JAMA Netw Open – year: 2021 ident: bib0025 article-title: FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system publication-title: Med (N Y) – year: 2021 ident: bib0031 article-title: Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study publication-title: The Lancet Infectious Diseases – volume: 384 start-page: 1576 year: 2021 end-page: 1577 ident: bib0032 article-title: Safety and Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med – volume: 108 start-page: 116 year: 2021 end-page: 118 ident: bib0041 article-title: The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout publication-title: Int J Infect Dis – year: 2021 ident: bib0009 article-title: Effectiveness of COVID-19 vaccines: From clinical trials to real life publication-title: Therapies – reference: Ministerio de Salud. "Efectividad de la vacuna CoronaVac con virus inactivo contra SARS-CoV-2 en Chile" Retrieved June 18, 2021, from – volume: 70 start-page: 396 year: 2021 end-page: 401 ident: bib0004 article-title: Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021 publication-title: MMWR Morb Mortal Wkly Rep – volume: 9 year: 2021 ident: bib0011 article-title: Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19 publication-title: Vaccines (Basel) – volume: 374 start-page: n2015 year: 2021 ident: bib0027 article-title: Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study publication-title: BMJ – volume: 69 start-page: 343 year: 2020 end-page: 346 ident: bib0034 article-title: Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 publication-title: MMWR Morb Mortal Wkly Rep – volume: 384 start-page: 1885 year: 2021 end-page: 1898 ident: bib0020 article-title: Effectiveness of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant publication-title: N Engl J Med – volume: 397 start-page: 1819 year: 2021 end-page: 1829 ident: bib0012 article-title: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data publication-title: The Lancet – year: 2021 ident: bib0024 article-title: Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization publication-title: Vaccine – volume: 323 start-page: 1239 year: 2020 end-page: 1242 ident: bib0039 article-title: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention publication-title: JAMA – year: 2021 ident: bib0013 article-title: Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study publication-title: Lancet Reg Health Am – reference: WHO. World Health Organization. "Tracking SARS-CoV-2 variants." Retrieved July 07, 2021, from https://www.who.int/activities/tracking-SARS-CoV-2-variants/tracking-SARS-CoV-2-variants. 2021a. – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: bib0003 article-title: Effectiveness and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med – volume: 28 start-page: 8077 year: 2010 end-page: 8084 ident: bib0010 article-title: Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans publication-title: Vaccine – volume: 373 start-page: n1088 year: 2021 ident: bib0019 article-title: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study publication-title: BMJ – volume: 20 start-page: 538 year: 2020 ident: bib0026 article-title: A systematic review assessing the under-representation of elderly adults in COVID-19 trials publication-title: BMC Geriatr – volume: 39 start-page: 4082 year: 2021 end-page: 4088 ident: bib0018 article-title: Interpreting vaccine effectiveness trial results for infection and transmission publication-title: Vaccine – reference: WHO. World Health Organization. ‘‘WHO Coronavirus Disease (COVID-19) Dashboard.” Retrieved October 15, 2021, from https://covid19.who.int/. 2021b. – volume: 8 start-page: ofab262 year: 2021 ident: bib0040 article-title: BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study publication-title: Open Forum Infect Dis – year: 2021 ident: bib0028 article-title: Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers publication-title: J Am Geriatr Soc – volume: 384 start-page: 1412 year: 2021 end-page: 1423 ident: bib0008 article-title: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting publication-title: N Engl J Med – start-page: 1 year: 2021 end-page: 32 ident: bib0017 article-title: Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study publication-title: Emerg Microbes Infect – reference: . – volume: 395 start-page: 1054 year: 2020 end-page: 1062 ident: bib0042 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: The Lancet – volume: 21 start-page: 853 year: 2020 ident: bib0023 article-title: Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Effectiveness and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial publication-title: Trials – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: bib0035 article-title: Safety and effectiveness of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The publication-title: Lancet – volume: 372 start-page: n71 year: 2021 ident: bib0022 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ – volume: 384 start-page: 1671 year: 2021 end-page: 1673 ident: bib0016 article-title: Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England publication-title: N Engl J Med – year: 2021 ident: bib0033 article-title: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening publication-title: Clin Infect Dis – reference: Wells. G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2011. Retrieved July 07, 2021, from – reference: . 2021. – year: 2021 ident: bib0014 article-title: Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile publication-title: N Engl J Med – volume: 69 start-page: 343 issue: 12 year: 2020 ident: 10.1016/j.ijid.2021.11.009_bib0034 article-title: Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6912e2 – volume: 397 start-page: 1819 issue: 10287 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0012 article-title: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data publication-title: The Lancet doi: 10.1016/S0140-6736(21)00947-8 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0031 article-title: Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study publication-title: The Lancet Infectious Diseases doi: 10.1016/S1473-3099(21)00289-9 – volume: 384 start-page: 1885 issue: 20 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0020 article-title: Effectiveness of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2102214 – volume: 323 start-page: 1239 issue: 13 year: 2020 ident: 10.1016/j.ijid.2021.11.009_bib0039 article-title: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention publication-title: JAMA doi: 10.1001/jama.2020.2648 – volume: 9 issue: 3 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0011 article-title: Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19 publication-title: Vaccines (Basel) – ident: 10.1016/j.ijid.2021.11.009_bib0038 – volume: 373 start-page: n1088 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0019 article-title: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study publication-title: BMJ doi: 10.1136/bmj.n1088 – volume: 13 start-page: 485 issue: 6 year: 2013 ident: 10.1016/j.ijid.2021.11.009_bib0021 article-title: AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(13)70046-X – ident: 10.1016/j.ijid.2021.11.009_bib0030 – ident: 10.1016/j.ijid.2021.11.009_bib0036 – volume: 385 start-page: 187 issue: 2 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0002 article-title: National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants publication-title: N Engl J Med doi: 10.1056/NEJMc2104974 – volume: 384 start-page: 1671 issue: 17 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0016 article-title: Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England publication-title: N Engl J Med doi: 10.1056/NEJMc2035906 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0025 article-title: FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system publication-title: Med (N Y) – volume: 384 start-page: 2187 issue: 23 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0029 article-title: Safety and Effectiveness of Single-Dose Ad26.COV2.S Vaccine against Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101544 – volume: 39 start-page: 4082 issue: 30 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0018 article-title: Interpreting vaccine effectiveness trial results for infection and transmission publication-title: Vaccine doi: 10.1016/j.vaccine.2021.06.011 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0014 article-title: Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile publication-title: N Engl J Med doi: 10.1056/NEJMoa2107715 – volume: 372 start-page: n71 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0022 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 395 start-page: 1054 issue: 10229 year: 2020 ident: 10.1016/j.ijid.2021.11.009_bib0042 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study publication-title: The Lancet doi: 10.1016/S0140-6736(20)30566-3 – volume: 28 start-page: 8077 issue: 51 year: 2010 ident: 10.1016/j.ijid.2021.11.009_bib0010 article-title: Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans publication-title: Vaccine doi: 10.1016/j.vaccine.2010.10.023 – start-page: 10 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0015 article-title: Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection publication-title: Elife – volume: 20 start-page: 538 issue: 1 year: 2020 ident: 10.1016/j.ijid.2021.11.009_bib0026 article-title: A systematic review assessing the under-representation of elderly adults in COVID-19 trials publication-title: BMC Geriatr doi: 10.1186/s12877-020-01954-5 – volume: 384 start-page: 1576 issue: 16 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0032 article-title: Safety and Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMc2036242 – volume: 108 start-page: 116 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0041 article-title: The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.05.021 – start-page: 1 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0017 article-title: Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study publication-title: Emerg Microbes Infect – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0033 article-title: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening publication-title: Clin Infect Dis – ident: 10.1016/j.ijid.2021.11.009_bib0037 – volume: 40 start-page: 83 year: 2018 ident: 10.1016/j.ijid.2021.11.009_bib0007 article-title: Vaccination in the elderly: The challenge of immune changes with aging publication-title: Semin Immunol doi: 10.1016/j.smim.2018.10.010 – volume: 4 issue: 6 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0006 article-title: Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.15985 – volume: 384 start-page: 1412 issue: 15 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0008 article-title: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting publication-title: N Engl J Med doi: 10.1056/NEJMoa2101765 – volume: 397 start-page: 99 issue: 10269 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0035 article-title: Safety and effectiveness of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – volume: 384 start-page: 403 issue: 5 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0003 article-title: Effectiveness and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0013 article-title: Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study publication-title: Lancet Reg Health Am – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0009 article-title: Effectiveness of COVID-19 vaccines: From clinical trials to real life publication-title: Therapies doi: 10.1016/j.therap.2021.05.004 – volume: 8 start-page: ofab262 issue: 6 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0040 article-title: BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofab262 – volume: 21 start-page: 853 issue: 1 year: 2020 ident: 10.1016/j.ijid.2021.11.009_bib0023 publication-title: Trials doi: 10.1186/s13063-020-04775-4 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0028 article-title: Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers publication-title: J Am Geriatr Soc doi: 10.1111/jgs.17180 – ident: 10.1016/j.ijid.2021.11.009_bib0001 – volume: 70 start-page: 396 issue: 11 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0004 article-title: Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7011e3 – volume: 374 start-page: n2015 year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0027 article-title: Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study publication-title: BMJ doi: 10.1136/bmj.n2015 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0005 article-title: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.06.036 – year: 2021 ident: 10.1016/j.ijid.2021.11.009_bib0024 article-title: Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.099 |
| SSID | ssj0004668 |
| Score | 2.6984804 |
| SecondaryResourceType | review_article |
| Snippet | •This study reports COVID-19 vaccine effectiveness (VE) in real-world settings.•COVID-19 VE for fully and partially vaccinated individuals.•COVID-19 VE for... To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Studies reporting COVID-19 VE... To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings.OBJECTIVETo estimate the... Objective: To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Methods: Studies... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 252 |
| SubjectTerms | Aged COVID-19 COVID-19 Vaccines Effectiveness Hospitalization Humans Real-world Review SARS-CoV-2 Vaccine Vaccine Efficacy |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals (ODIN) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_SQxFEtH5t_SCCN4nuJpts1lutlipUQVrpLUy-8JW6r9hX_34zm-zynkJ78RZ2M7tkZpKZJDO_IeRV2va42gXBgsRrRgUKy7xEpkVQIGrn2oDnkEdf1OFJ-_lUnq6V-sKYsAwPnBn3VrWdbFQMXnveesX7GLiPUFuudeAq4uqbbN60mZozInMSXDJvrO8aXtJlcmTX4myBGKG8eYP4nRiKuGaSRuT-Dcv0r-f5dwDlmkU6uEfuFleS7uUh3Ce3wrBDto_KZfkOuZOP5GjONHpAjr-lBhshUmkO4ygrHV1Guv_1-6cPrOnpb3BIfvmOAj2fMZdpTnGhMHj6M6yAQQEzeUhODj4e7x-yUlSBuTTVVqx1HmTwoefeWeuV9dbGpo5CQvLGQHQyQOMgNWziN7dWtio6GaUA6bTX4hHZGpZDeEIod1AL7ZTHTjJG6DFWNcraCoWYOhVpJr4aVxDHsfDFuZlCy84MysKgLNJWxCRZVOT1THOR8Tau7f0exTX3RKzs8UHSIFM0yNykQRURk7DNlI6aFtD0ocW1v5YzVXFWshNyI93LSZ9Mmsl4PQNDWF5dGiwVkJwF0emKPM76NQ9MtBqTebqKdBuatzHyzTfD4seIFo4Adn0nd_8Hq56S2xzTP8YjqGdka_XrKjxPTtnKvhjn3x_MWzRN priority: 102 providerName: Directory of Open Access Journals |
| Title | Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971221008572 https://dx.doi.org/10.1016/j.ijid.2021.11.009 https://www.ncbi.nlm.nih.gov/pubmed/34800687 https://www.proquest.com/docview/2600284378 https://pubmed.ncbi.nlm.nih.gov/PMC8595975 https://doaj.org/article/647516fed8d24d629fe2dfa0b288e26f |
| Volume | 114 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhASQlBe4VEZiRtKN7ZjJ-FGt1RdUEGCFu3N8hNSlWzVbjny2_HETrQBqUhcIisZJ3FmPJ7Y831G6FX47TGFcSx3HJYZhRKwzYvPa-aEYoUxpYN5yOOP4ui0fL_kyy00H7AwkFaZfH_06b23Tmdm6WvOLtp29oWEsaupCKWkp2kHP1yWFVj53i-ygY2McLggnIN0As7EHK_2rAW2UEr2gMkTkhI3Bqeew38yRv0dg_6ZSrkxNh3eQ3dTUInfxve-j7Zct4NuHadl8x10J07O4Yg5eoBOPodC3pOl4pjQkXweXnk8__R1cZCTBv9UBqpfvcEKn4_syziCXbDqLP7h1ipXidbkITo9fHcyP8rT9gq5CZ1unZfGKu6sa6g1WluhrdaeFJ5xFeIyxSruFDEqFDQtLdWal8Ib7jlT3NS2Zo_Qdrfq3BOEqVEFq42wIMS9Vw1krXpeaCaAXSdDZPiu0iTucdgC41wOSWZnEnQhQRfhp0QGXWTo9VjnIjJv3Ci9D-oaJYE1uz-xuvwmk9lIUVacCO9sbUOLBG28o9arQtO6dlT4DLFB2XIApgZXGm7U3vhoPtaamO4_670c7EmGPg0LNapzq-srCZsGhLCBVXWGHkf7GhvGyhpgPVWGqonlTVo-vdK133vecKCyayr-9D_f9xm6TQH70c8_PUfb68tr9yJEZGu923e5cDxYfNjtZzXCcbHc_w10dDbs |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkaASQlBe4WkkOKF0Ezt2EiQO0FLt0m6RYIt6M36WVCVbdbcgLvwp_iCexIl2QSoSUm9R1s7anvF4bM_3DULP_LZHJ9rS2DK4ZuSSQ5oXFxfUckkTrTML55DjPT7cz94dsIMV9KvDwkBYZbD9rU1vrHV4MwijOTipqsHH1K9dZZ4SkjY07SREVu7YH9_9vm32arTlhfyckO23k81hHFILxNor3DzOtJHMGlsSo5UyXBmlXJo4yqT3SSTNmZWplv5BkcwQpVjGnWaOUcl0YQrqv3sJXc68uYC0CRs_0wUwZou_862LoXkBqdMGlVVHFdCTknQDqEMhCnJhNWySBiwtin87vX_Gbi4shts30PXgxeLX7UDdRCu2XkdXxuGefh1da08DcQtyuoUmH_xD3LCz4jaCJBhZPHV48_2n0Vaclvib1FB99hJLfNzTPeMWXYNlbfBXO5exDDwqt9H-hQz6HbRaT2t7D2GiZUILzQ0UYs7JEsJkHUsU5UDnE6G0G1ehA9k55Nw4Fl1U25EAWQiQhd8FCS-LCL3o65y0VB_nln4D4upLAk1382J6eiiCngqe5SzlzprC-B5xUjpLjJOJIkVhCXcRop2wRYeE9bbbf6g6969ZX2tprvyz3tNOn4Q3InAzJGs7PZsJyFLg_RSaFxG62-pX3zGaFYAjyiOUL2neUs-Xf6mrLw1ROXDnlTm7_5_tfYKuDifjXbE72tt5gNYIAE-aw6-HaHV-emYfeXdwrh430w-jzxc9338DODd0gg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-world+effectiveness+of+COVID-19+vaccines%3A+a+literature+review+and+meta-analysis&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Zheng%2C+Caifang&rft.au=Shao%2C+Weihao&rft.au=Chen%2C+Xiaorui&rft.au=Zhang%2C+Bowen&rft.date=2022-01-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.eissn=1878-3511&rft.volume=114&rft.spage=252&rft.epage=260&rft_id=info:doi/10.1016%2Fj.ijid.2021.11.009&rft.externalDocID=S1201971221008572 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |